Zensar Technologies Board Approves Merger of US Subsidiaries into Zensar Technologies Inc., USA

Zensar Technologies Board Approves Merger of US Subsidiaries into Zensar Technologies Inc., USA​

Zensar Technologies Limited's Board of Directors has granted in-principle approval for a significant merger involving two US-based step-down subsidiaries and its wholly owned subsidiary, Zensar Technologies Inc., USA.

The decision was taken by the company’s Board of Directors at a meeting held on July 29, 2026. The merger involves Bridgeview Life Sciences LLC and M3BI LLC, which will be merged into Zensar Technologies Inc., USA, either directly or indirectly through the creation of a new entity.

Following the completion of the merger, the Merging Entities are set to cease existing as step-down subsidiaries of Zensar Technologies Limited. The boards and shareholders of Bridgeview Life Sciences LLC, M3BI LLC, and Zensar Technologies Inc., USA will separately consider the proposed merger.

Business Profile and Merger Rationale​

The entities involved in the merger share a common focus on providing digital solutions and technology services to global organizations. The rationale provided for undertaking the transaction is to achieve greater business synergies and higher operational efficiencies, which will also lead to effective management and unified control of operations across all merging parties. There will be no change in the shareholding pattern of Zensar Technologies Limited consequent to this merger.

Financial Overview of Merging Entities​

The companies involved in the proposed merger possess substantial size and turnover. The details pertaining to the entities as on and for the year ended March 31, 2026 are summarized below:

ZENSARTECH Stock Price Movement​

Today, Zensar Technologies Limited shares edged higher to close at ₹534.95 after gaining 1.97%. The stock saw brisk trading today on a volume of 4.71 million shares, moving within a range established between a low of ₹529 and a high of ₹553.1.